The risk for developing cardiovascular diseases (CVD) in rheumatoid arthritis (RA) patients
is 1.5 times higher compared to the general population. This risk is partly due to the …

There is concern that people with rheumatic disease, often treated with immunosuppressive
or immunomodulatory medication, may be at an increased risk of poor outcomes of novel …

Objectives To estimate the incidence of COVID-19 hospitalization in patients with
inflammatory rheumatic disease (IRD); in patients with RA treated with specific DMARDs; …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

В середине 2021 года инфекция SARS-CoV-2 (Severe Acute Respiratory coronavirus 2),
вызвавшая пандемию коронавирусной болезни 2019 (coronavirus disease, COVID-19) …

Aim To assess the impact of the COVID-19 pandemic on patients with rheumatic and
musculoskeletal diseases (RMDs). Methods REUMAVID is a cross-sectional study using an …

Aims In Danish patients with inflammatory rheumatic diseases to explore self-protection
strategies and health behaviour including adherence to disease-modifying antirheumatic …

Background There is a paucity of data on outcomes for people with gout and COVID-19. We
aimed to assess whether gout is a risk factor for diagnosis of COVID-19 and COVID-19 …

Glucocorticoids, but not other DMARDs, are associated with a higher risk of severe COVID-
19 outcomes in RA patients. Further studies are needed to explore the impact of specific …

Objective To determine the effect of a multidisciplinary lifestyle program in patients with RA
with low–moderate disease activity. Methods In the 'Plants for Joints'(PFJ) parallel-arm …